Original article / research
|
||||||
Intensity and Grading of Galectin-3 Expression as a Sole Marker to Differentiate Benign and Malignant Thyroid Neoplasms |
||||||
| Correspondence
Address : Dr. Kondisetty Gowrinath, Assistant Professor, Department of General Surgery, Medicity Institute of Medical Sciences, Ghanpur, Medchal, Telangana, India. E-mail: docsunnyhyd@gmail.com |
||||||
 |
||||||
|
Introduction: Errors in categorization of thyroid neoplasms as benign or malignant has management implications. In several studies Galectin-3 was one of the most reliable markers for malignancy in thyroid. Aim: To evaluate utility of Galectin-3 as a sole marker in differentiating benign and malignant thyroid neoplasm. Materials and Methods: Forty one thyroidectomy cases were studied, which included 12 benign and 29 malignant thyroid neoplasms. Galectin-3 (CELL MARQUE Galectin-3 mouse monoclonal antibody, CMC25521020) expression was assessed. Grading based on intensity and extent (diffuse/focal) of Galectin-3 expression was also noted. Results: The expression of Galectin-3 was significantly higher (p<0.001) in malignant thyroid neoplasms. Difference in Galectin-3 expression in benign thyroid neoplasms and PTC was significant (p<0.001). Galectin-3 expression within various follicular neoplasms was not useful when only positivity (>10% of cells positive) (p>0.08) and diffuse positivity (>50% of cells positive) (p>0. 0.167) were taken into consideration. However, with grade 3 intensity of Galectin- 3 staining in various follicular neoplasms there was a significant difference in Galectin-3 expression (p<0.002). Conclusion: Galectin-3 is useful in differentiating benign and malignant thyroid neoplasm (p<0.05). It can be used as sole marker for differentiating Papillary thyroid carcinoma and benign thyroid neoplasms. Grade 3 intensity of Galectin-3 positivity could prove to be a useful marker in differentiating follicular patterned lesions. |
||||||
[ FULL
TEXT ] | [   ]
|
||||||
|
||||||
